NYSE:MED Medifast (MED) Stock Price, News & Analysis $13.73 -0.04 (-0.30%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$13.75 +0.02 (+0.15%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Medifast Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medifast alerts:Sign Up Key Stats Today's Range$13.39▼$13.8850-Day Range$12.48▼$15.2252-Week Range$11.57▼$21.98Volume201,903 shsAverage Volume197,000 shsMarket Capitalization$150.90 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingHold Company Overview Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland. Read More Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 70% of companies evaluated by MarketBeat, and ranked 71st out of 150 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedifast has received no research coverage in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.30% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Medifast has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted21.30% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Medifast has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.11 News SentimentMedifast has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Medifast this week, compared to 3 articles on an average week.Search Interest3 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,003.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMedifast (MED) Projected to Post Earnings on Monday3 hours ago | americanbankingnews.comMedifast (MED) Earnings Report: Anticipated Decline in Q2 PerformanceAugust 1 at 10:09 PM | gurufocus.comThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Medifast Q2 2025 Earnings PreviewAugust 1 at 3:19 PM | seekingalpha.com3 Unpopular Stocks We Keep Off Our RadarJuly 30 at 11:15 PM | msn.comHead to Head Analysis: Cuisine Solutions (OTCMKTS:CUSI) & Medifast (NYSE:MED)July 27, 2025 | americanbankingnews.comMedifast to Announce Financial Results for the Second Quarter Ended June 30, 2025July 21, 2025 | businesswire.comMedifast Inc. Company & People | MED | Barron'sJuly 7, 2025 | barrons.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $17.62 at the beginning of the year. Since then, MED shares have decreased by 22.1% and is now trading at $13.7290. How were Medifast's earnings last quarter? Medifast Inc (NYSE:MED) posted its quarterly earnings results on Monday, April, 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.04. The specialty retailer earned $115.73 million during the quarter, compared to the consensus estimate of $114.85 million. Medifast had a positive trailing twelve-month return on equity of 6.63% and a negative net margin of 1.29%. Read the conference call transcript. Who are Medifast's major shareholders? Medifast's top institutional shareholders include Peapod Lane Capital LLC (0.79%), SummerHaven Investment Management LLC (0.39%), Allianz Asset Management GmbH (0.20%) and Chickasaw Capital Management LLC (0.13%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AU Optronics (AUOTY). Company Calendar Last Earnings4/28/2025Today8/02/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry FOOD - MISC/DIVERSIFIED Sub-IndustryPersonal Products Current SymbolNYSE:MED CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Price Target for Medifast$16.50 High Price Target$16.50 Low Price Target$16.50 Potential Upside/Downside+20.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E Ratio26.92 P/E GrowthN/ANet Income$2.09 million Net Margins-1.29% Pretax Margin-1.34% Return on Equity6.63% Return on Assets4.81% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio2.87 Sales & Book Value Annual Sales$602.46 million Price / Sales0.25 Cash Flow$2.93 per share Price / Cash Flow4.69 Book Value$19.21 per share Price / Book0.71Miscellaneous Outstanding Shares10,990,000Free Float10,672,000Market Cap$150.88 million OptionableOptionable Beta0.80 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:MED) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.